Get started
Author

Sivuonthanh Lam

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
2018 · Leora Horn, Aaron S. Mansfield, et al. · New England Journal of Medicine · 3,578
PDF
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
2021 · Stephen V. Liu, Martin Reck, et al. · Journal of Clinical Oncology · 860
PDF
Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial
2020 · A.S. Mansfield, A. Każarnowicz, et al. · Annals of Oncology · 193
PDF
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide
2023 · Stephen V. Liu, Tony S.K. Mok, et al. · Lung Cancer · 50
PDF
Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide
2022 · Martin Reck, Tony S.K. Mok, et al. · Journal of Thoracic Oncology · 31
PDF
Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer
2020 · Anne C. Chiang, Lecia Van Dam Sequist, et al. · Clinical Lung Cancer · 26
PDF
PS01.56: IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1–Selected Chemotherapy-Naive NSCLC Patients
2016 · Roy S. Herbst, Filippo De Marinis, et al. · Journal of Thoracic Oncology · 7
Abstract CT199: IMpower133: Primary efficacy and safety + CNS-related adverse events in a Ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)
2019 · Aaron S. Mansfield, Stephen V. Liu, et al. · Cancer Research · 5
PS01.57: IMpower133: a Phase I/III Study of 1L Atezolizumab with Carboplatin and Etoposide in Patients with Extensive-Stage SCLC
2016 · Leora Horn, Martin Reck, et al. · Journal of Thoracic Oncology · 5
Phase I/III trial of atezolizumab with carboplatin and etoposide in ES-SCLC in first-line setting (IMpower133).
2017 · Leora Horn, Aaron Scott Mansfield, et al. · Journal of Clinical Oncology · 3
Abstract CT220: IMpower133: Updated OS and exploratory analyses of first-line (1L) atezolizumab (atezo) + carboplatin (C) + etoposide (E) in extensive-stage SCLC (ES-SCLC)
2020 · Leora Horn, Stephen V. Liu, et al. · Cancer Research · 2
EP1.12-06 New Treatment Option for ES-SCLC: Patient Characteristics and Use of an Atezolizumab Regimen in the Real-World Setting
2019 · S. Mccune, T. Ton, et al. · Journal of Thoracic Oncology · 2
P3.02c-041 IMpower133: A Phase I/III Study of 1L Atezolizumab with Carboplatin and Etoposide in Patients with Extensive-Stage SCLC
2017 · Stephen Liu, Martin Reck, et al. · Journal of Thoracic Oncology · 2
Abstract CT199: IMpower133: Primary efficacy and safety + CNS-related adverse events in a Ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)
2019 · Aaron S. Mansfield, Stephen V. Liu, et al. · Clinical Trials
P3.02c-042 IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1–Selected Chemotherapy-Naive NSCLC Patients
2017 · Filippo De Marinis, Jacek Jassem, et al. · Journal of Thoracic Oncology
Works count: 15
Citation count: 4,762
H-index: 7
I10-index: 6
Year
Topic
Type